[PDF] Top 20 Reducing Variation in the Use of Inhaled Nitric Oxide

... simplify use; education and training of the CTICU staff regarding the guidelines and goals; obtaining CTICU staff buy-in and accountability; and development of outcome and compliance ... See full document

... the Nitric Oxide Chronic Lung Disease (NOCLD) study group, the use of bronchodilators, inhaled steroids, systemic steroids, diuretics, and supplemental oxygen during the fi rst year of life was ... See full document

... in use of INO on the day of CDH repair (OR ...ECMO use (23% overall, hospital range 0% – 52%), days of ECMO therapy per treated in- fant, and rate of CDH repair did not change signi fi cantly over the study ... See full document

... It may be argued that withdrawal of iNO is not to blame. Instead, the hypoxemia may be caused by the progression of the underlying pathophysiology. However, the dose-dependent nature of the degree of hypoxemia and the ... See full document

... the use of iNO should be consid- ered only after careful echocardiographic examina- tion to rule out structural and functional contraindi- cations (anatomic defects with ductal dependent systemic blood flow or ... See full document

... physiologic effect likely leads many neonatologists to attribute the survival of iNO-exposed neonates to iNO therapy, when in fact a number of other factors could have led to that infant’s outcome. We acknowledge that it ... See full document

... Since the toxic effects of NO are partly dose-dependent, it is essential to use the lowest effective dose. The appropriate dose of iNO is, however, debated. Recommended start dose of iNO in infants with persistent ... See full document

... The proposed guidelines need to leave room for individual clinician judgment but could require parental consent by using a consent document approved by the institutional review board with agreed language before iNO is ... See full document

... Recently, new therapeutic modalities, such as inhaled nitric oxide (INO), have been used in the treatment of PPHN (2). INO acts as a pulmonary vasodilator by activating guanylate cyclase, which leads ... See full document

... enrolled intubated preterm infants (gestational age of ⬍ 34 weeks and birth weight of ⬍ 2 kg) at ⬍ 72 hours of age, without additional criteria regarding severity of ill- ness. This was a 2 ⫻ 2 factorial design examining ... See full document

... routine use of iNO (treatment in the first 3 days after birth); (2) early rescue treatment based on oxygenation inclusion; and (3) enroll- ment based on increased risk of BPD ⱖ 4 days after ... See full document

... We demonstrate that off-label prescription of iNO is not associated with improved survival in a large cohort of extremely premature neonates with RDS. Among subjects whose RDS was associated with PPHN, treatment with iNO ... See full document

... the use of low-dose iNO may result in sustained improvement in oxygenation in some infants with severe BPD, allowing them to tolerate lower inspired oxygen concentrations and decreased ventilator ...of ... See full document

... Exclusion criteria were ⬎ 14 days of postnatal age, life-threat- ening congenital malformations, structural heart disease other than patent ductus arteriosus or patent foramen ovale, congenital diaphragmatic hernia, or ... See full document

... and no iNO, and their initial OIs were 34 to 37, substantially higher than the current study. Infants with OIs that exceeded 35 then were treated with 20 ppm of iNO. Their study found a greater fall in OI and improvement ... See full document

... constriction), selected as the worst and best performing devices, respectively, in the experimental study. For the injection and mixing element, simulations indicated enhanced mixing between the NO-containing gas stream ... See full document

... the use of iNO for premature infants with chronic lung ...expanded use of iNO awaits the results of the ran- domized, controlled trials that are proposed by Banks and associates in this issue of ... See full document

... Our study, the only multicentered epidemiologic investigation of a cohort of neonates with PPHN ever analyzed, suggests that the optimal treatment of ne- onates with PPHN before the use of inhaled ... See full document

... fact nitric oxide (NO), it offered doctors the opportunity to use, for the first time, a selective pulmonary vasodilator in a variety of patient ...increased use of surfactant and antenatal ... See full document

... The standard search strategy of the Cochrane Neonatal Review Group will be used to identify potentially eligible studies. This involves extensive searching of bibliographic databases such as MEDLINE, EMBASE.com, The ... See full document